Cannabinoid Receptors and Endocannabinoids: Role in Neuroinflammatory and Neurodegenerative Disorders

Huntington's Disease Alzheimer's Disease Parkinson's Disease Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease) Multiple Sclerosis (MS)

Key Findings

The neuro-modulatory actions at CB1 receptors by endocannabinoids, of which anandamide and 2-arachidonoylglycerol are the two most studied representatives, allows them to counteract the neuro-chemical imbalances arising during Alzheimer’s disease, multiple sclerosis, amyotropic lateral sclerosis, Parkinson’s disease, and Huntington’s chorea.

Information and Links


Link: Cannabinoid Receptors and Endocannabinoids: Role in Neuroinflammatory and Neurodegenerative Disorders

Year: 2010

DOI: 10.2174/187152710793361568


Ratings

(How Ratings Work)

Huntington's Disease — 3


Likely probability of the efficacy of cannabis for treatment of Huntington's Disease according to the results found in this study.

Alzheimer's Disease — 3


Likely probability of the efficacy of cannabis for treatment of Alzheimer's Disease according to the results found in this study.

Parkinson's Disease — 3


Likely probability of the efficacy of cannabis for treatment of Parkinson's Disease according to the results found in this study.

Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease) — 3


Likely probability of the efficacy of cannabis for treatment of Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease) according to the results found in this study.

Multiple Sclerosis (MS) — 3


Likely probability of the efficacy of cannabis for treatment of Multiple Sclerosis (MS) according to the results found in this study.

Drugs Used

Cannabinoids

Endocannabinoids